Vessby B, Lithell H, Boberg J
Artery. 1981;9(5):372-81.
The question whether serum lipid lowering treatment will reduce the incidence of coronary heart disease (CHD) has been a matter of intense debate during the last few years. When analysing the results from the major preventive trials, it can be concluded that there is no unequivocal evidence that lipid lowering treatment will reduce the death rate in CHD. However, the great majority of the trials performed have shown a reduced number of CHD deaths in the treatment group, compared with the control group. There is strong evidence that lipid lowering treatment of hyperlipidaemic patients will reduce the incidence of non-fatal myocardial infarctions. This reduction is directly proportional to the degree of cholesterol lowering achieved.
在过去几年中，血清降脂治疗是否会降低冠心病（CHD）的发病率一直是激烈争论的话题。在分析主要预防性试验的结果时，可以得出结论，没有明确的证据表明降脂治疗会降低冠心病的死亡率。然而，进行的绝大多数试验表明，与对照组相比，治疗组的冠心病死亡人数有所减少。有强有力的证据表明，对高脂血症患者进行降脂治疗将降低非致命性心肌梗死的发病率。这种降低与所达到的胆固醇降低程度成正比。
